Acutis Biosciences opens AI-powered biomarker analysis unit for trials sector
Acutis Biosciences opened a new clinical biomarker analysis facility at its base in Monmouth, New Jersey last week.
The 60,000 square-foot unit houses biomarker profile labs as well as dedicated data analysis capacity.
Acutis also said activities at the site will leverage expertise gained through its standard-of-care business, Acutis Diagnostics, which has processed over three million patient samples over the past seven years.
The idea, according to CEO Jibreel Sarij, is to provide drug developers with a single point of contact that offers both biomarker identification and analysis in a bid to accelerate their product development efforts.
"We are re-imagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics and are rewriting the rules to champion our biopharma partners.
“Far too often, we have heard about the industry's dissatisfaction with CROs, whether it be slow turnaround time, incomplete data analytics, or missed opportunities to advance drug discovery with robust biomarker analytics.”
Researchers working at the new facility will also make use of cutting-edge technology to aid the biomarker identification process Sarij said.
“We are investing in the machine learning AI tools that will become increasingly important in the interpretation of the complex data sets that our multi-omics analyses will yield."
The opening of the facility coincided with the appointment of Troy Tremaine as Acutis’ chief commercial officer. Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients' success.
According to Acutis Tremaine brings over 26 years of experience within the life sciences and clinical research organization (CRO) industry and his experience in fostering strategic partnerships, implementing customer-focused programs, and growing complex businesses.
Acutis Biosciences in a member of the Acutis Family of companies, and is a provider of biomarker-based analysis, as well as assay development.
In addition to the New Jersey unit, the firm operate a CAP, CLEP, CLIA accredited 40,000 square-foot facility in New York and a technology center in Hyderabad, India.
Unsplash/sonance